A Prospective Evaluation of Natriuretic Peptide Based Referral of CHF Patients in Primary Care (PREFER)

This low interventional study, whose unique intervention was to measure the blood level of a biomarker called NT-proBNP in chronic heart failure patients daily followed-up by Primary Care Physicians (PCPs) in Europe, assessed if the cardiologist referral guided by NT-proBNP measurement in patients who were currently judged by PCPs as being stable, would lead to optimization of HF treatment, defined in adherence to treatment recommendations of the current European Society of Cardiology guidelines for the treatment of heart failure.

Study Overview

• Status: Completed
• Conditions: Chronic Heart Failure (CHF)
• Intervention / Treatment: Procedure: Standard care

Detailed Description

In the majority of European countries, the primary management of chronic heart failure patients was performed by General Practitioners in collaboration with cardiologists (specialists). Previous studies had shown that many patients suffering from CHF do not receive optimal pharmacological and/or device treatment for their disease. An increase in natriuretic peptides (BNP, NT-proBNP) was associated with increased risk of cardiovascular events in heart failure patients. The purpose of the present study was to assess if a referral of clinical stable chronic heart failure patients with reduced ventricular ejection fraction (EF < or = 40%) and NT-proBNP level > or = 600 pg/mL to a specialist (cardiologist) led to treatment optimization, defined as adherence to the treatment recommendations according to the European Society of Cardiology (ESC) guidelines. In addition, data obtained in this study was used to describe demographic, clinical (including NT-proBNP levels) and treatment characteristics of CHF patients who were managed in the primary care setting across Europe..

• Study Type: Interventional
• Enrollment (Actual): 1415
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Aarschot, Belgium, 3200
    • Novartis Investigative Site
  • Alveringem, Belgium, 8691
    • Novartis Investigative Site
  • Boezinge, Belgium, 8904
    • Novartis Investigative Site
  • Bruxe, Belgium, 1080
    • Novartis Investigative Site
  • Buggenhout, Belgium, Belgium, 9255
    • Novartis Investigative Site
  • Deinze, Belgium, 9800
    • Novartis Investigative Site
  • Deurne, Belgium, 2100
    • Novartis Investigative Site
  • Diksmuide, Belgium, 8600
    • Novartis Investigative Site
  • Ezemaal-Neerwinden, Belgium, 3400
    • Novartis Investigative Site
  • Hasselt, Belgium, 3500
    • Novartis Investigative Site
  • Hasselt, Belgium, Belgium, 3500
    • Novartis Investigative Site
  • Herzele, Belgium, 9550
    • Novartis Investigative Site
  • Kluisbergen, Belgium, 9690
    • Novartis Investigative Site
  • Landen, Belgium, 3400
    • Novartis Investigative Site
  • Leefdaal, Belgium, 3060
    • Novartis Investigative Site
  • Linkebeek, Belgium, 1630
    • Novartis Investigative Site
  • Lommel, Belgium, 3920
    • Novartis Investigative Site
  • Maasmechelen, Belgium, 3630
    • Novartis Investigative Site
  • Mont sur Marchienne, Belgium, 6032
    • Novartis Investigative Site
  • Nazareth, Belgium, 9810
    • Novartis Investigative Site
  • OOsteeklo, Belgium, 9988
    • Novartis Investigative Site
  • Oostende, Belgium
    • Novartis Investigative Site
  • Oudenaarde, Belgium, 9700
    • Novartis Investigative Site
  • Saint-Medard, Belgium, 6887
    • Novartis Investigative Site
  • Stoumont, Belgium, 4987
    • Novartis Investigative Site
  • Tessenderlo, Belgium, 3980
    • Novartis Investigative Site
  • Thuilles, Belgium, 6536
    • Novartis Investigative Site
  • Tielt-Winge, Belgium, 3390
    • Novartis Investigative Site
  • Tremelo, Belgium, 3120
    • Novartis Investigative Site
  • Vilvoorde, Belgium, 1800
    • Novartis Investigative Site
  • Waregem, Belgium, 8790
    • Novartis Investigative Site
  • BEL
    • Binkom, BEL, Belgium, 3211
      • Novartis Investigative Site
    • Gozee, BEL, Belgium, 6534
      • Novartis Investigative Site
    • Linkebeek, BEL, Belgium, 1630
      • Novartis Investigative Site
    • Oostham, BEL, Belgium, 3945
      • Novartis Investigative Site
    • Zichem, BEL, Belgium, 3271
      • Novartis Investigative Site
• Croatia
  • Bizovac, Croatia, 31222
    • Novartis Investigative Site
  • HRV, Croatia, 10000
    • Novartis Investigative Site
  • HRV, Croatia, 31000
    • Novartis Investigative Site
  • HRV, Croatia, 42000
    • Novartis Investigative Site
  • HRV, Croatia, 44320
    • Novartis Investigative Site
  • Krasica, Croatia, 51224
    • Novartis Investigative Site
  • Osijek, Croatia, 31000
    • Novartis Investigative Site
  • Rijeka, Croatia, 51000
    • Novartis Investigative Site
  • Slavonski Brod, Croatia, 35000
    • Novartis Investigative Site
  • Velika Kopanica, Croatia, 35221
    • Novartis Investigative Site
  • Viskovo, Croatia, 51216
    • Novartis Investigative Site
  • Zagreb, Croatia, 10000
    • Novartis Investigative Site
  • HRV
    • Rijeka, HRV, Croatia, 51000
      • Novartis Investigative Site
    • Visnjevac, HRV, Croatia, 31220
      • Novartis Investigative Site
    • Zagreb, HRV, Croatia, 10000
      • Novartis Investigative Site
• Cyprus
  • Nicosia, Cyprus, 2048
    • Novartis Investigative Site
  • Nicosia, Cyprus, 2540
    • Novartis Investigative Site
• Denmark
  • Præstø, Denmark, 4720
    • Novartis Investigative Site
  • Skive, Denmark, 7800
    • Novartis Investigative Site
• Estonia
  • Paide, Estonia, 72713
    • Novartis Investigative Site
  • Tallinn, Estonia, 10138
    • Novartis Investigative Site
  • Tallinn, Estonia, 11911
    • Novartis Investigative Site
  • Tallinn, Estonia, 13415
    • Novartis Investigative Site
  • EST
    • Someru, EST, Estonia, 44201
      • Novartis Investigative Site
• France
  • Arras, France, 62000
    • Novartis Investigative Site
  • Bersee, France, 59254
    • Novartis Investigative Site
  • Breteuil Sur Seine, France, 27160
    • Novartis Investigative Site
  • Cannes, France, 06400
    • Novartis Investigative Site
  • Chantepie, France, 35135
    • Novartis Investigative Site
  • Colombiers, France, 31770
    • Novartis Investigative Site
  • Coursan, France, 11110
    • Novartis Investigative Site
  • Erquy, France, 22430
    • Novartis Investigative Site
  • La Seyne-sur-Mer, France, 83500
    • Novartis Investigative Site
  • Laval, France, 53000
    • Novartis Investigative Site
  • Les Pennes Mirabeau, France, 13170
    • Novartis Investigative Site
  • Negrepelisse, France, 82800
    • Novartis Investigative Site
  • Orthez, France, 64300
    • Novartis Investigative Site
  • Paris, France, 75010
    • Novartis Investigative Site
  • Paris, France, 75020
    • Novartis Investigative Site
  • Rosiers d'Egleton, France, 19300
    • Novartis Investigative Site
  • Salles, France, 33770
    • Novartis Investigative Site
  • Six Fours, France, 83140
    • Novartis Investigative Site
  • St orens de Gameville, France, 31650
    • Novartis Investigative Site
  • Strasbourg, France, 67200
    • Novartis Investigative Site
• Hungary
  • Balatonkeresztur, Hungary, 8647
    • Novartis Investigative Site
  • Budapest, Hungary, 1136
    • Novartis Investigative Site
  • Csongrad, Hungary, 6640
    • Novartis Investigative Site
  • Erd, Hungary, 2030
    • Novartis Investigative Site
  • Felsorajk, Hungary, 8767
    • Novartis Investigative Site
  • Hosszuheteny, Hungary, 7694
    • Novartis Investigative Site
  • Kecskemet, Hungary, 6000
    • Novartis Investigative Site
  • Korondi, Hungary, 6726
    • Novartis Investigative Site
  • Nyiregyhaza, Hungary, 4400
    • Novartis Investigative Site
  • Pecs, Hungary, 7632
    • Novartis Investigative Site
  • Szabadsag, Hungary, 6756
    • Novartis Investigative Site
  • Szeged-Szoreg, Hungary, H-6771
    • Novartis Investigative Site
  • Szekesfehervar, Hungary, 8000
    • Novartis Investigative Site
  • Torokbalint, Hungary, 2045
    • Novartis Investigative Site
  • Zakanyszek, Hungary, 6787
    • Novartis Investigative Site
• Israel
  • Beer Sheva, Israel, 8477713
    • Novartis Investigative Site
• Italy
  • BG
    • Grumello Del Monte, BG, Italy, 24064
      • Novartis Investigative Site
  • FC
    • Gatteo, FC, Italy, 47043
      • Novartis Investigative Site
• Latvia
  • Riga, Latvia, 1012
    • Novartis Investigative Site
  • Riga, Latvia, LV-1006
    • Novartis Investigative Site
  • Riga, Latvia, LV-1021
    • Novartis Investigative Site
  • LVA
    • Jelgava, LVA, Latvia, LV-3001
      • Novartis Investigative Site
    • Riga, LVA, Latvia, LV 1010
      • Novartis Investigative Site
• Lithuania
  • Alytus, Lithuania, LT-62386
    • Novartis Investigative Site
  • Kaunas, Lithuania, LT-49387
    • Novartis Investigative Site
  • Kaunas, Lithuania, LT-49449
    • Novartis Investigative Site
  • Vilnius, Lithuania, LT-08661
    • Novartis Investigative Site
  • LTU
    • Kaunas, LTU, Lithuania, LT 50161
      • Novartis Investigative Site
    • Kaunas, LTU, Lithuania, LT 45488
      • Novartis Investigative Site
    • Klaipeda, LTU, Lithuania, 92304
      • Novartis Investigative Site
• Malta
  • Rabat, Malta
    • Novartis Investigative Site
  • Gozo
    • Xaghra, Gozo, Malta, XRA 2405
      • Novartis Investigative Site
    • Xewkija, Gozo, Malta, VCT 110
      • Novartis Investigative Site
• Norway
  • Flisa, Norway, 2270
    • Novartis Investigative Site
  • Hamar, Norway, 2317
    • Novartis Investigative Site
  • Honefoss, Norway, 3515
    • Novartis Investigative Site
  • Kirkenær, Norway, 2260
    • Novartis Investigative Site
  • Lierskogen, Norway, N-3420
    • Novartis Investigative Site
  • Loten, Norway, 2340
    • Novartis Investigative Site
  • Lørenskog, Norway, 1473
    • Novartis Investigative Site
  • Noetteroey, Norway, 3163
    • Novartis Investigative Site
  • Ostereidet, Norway, 5993
    • Novartis Investigative Site
  • Skien, Norway, 3734
    • Novartis Investigative Site
• Poland
  • Bialystok, Poland, 15-746
    • Novartis Investigative Site
  • Bialystok, Poland, 15-867
    • Novartis Investigative Site
  • Bielawa, Poland, 58-260
    • Novartis Investigative Site
  • Bydgoszcz, Poland, 85-021
    • Novartis Investigative Site
  • Dzierzoniow, Poland, 58-200
    • Novartis Investigative Site
  • Katowice, Poland, 40-018
    • Novartis Investigative Site
  • Krakow, Poland, 30 415
    • Novartis Investigative Site
  • Krakow, Poland, 30-664
    • Novartis Investigative Site
  • Krakow, Poland, 31-061
    • Novartis Investigative Site
  • Lublin, Poland, 20-094
    • Novartis Investigative Site
  • Miasteczko Slaskie, Poland, 42-610
    • Novartis Investigative Site
  • Poznan, Poland, 61-388
    • Novartis Investigative Site
  • Warszawa, Poland, 01-493
    • Novartis Investigative Site
  • Warszawa, Poland, 01-887
    • Novartis Investigative Site
  • Warszawa, Poland, 03 185
    • Novartis Investigative Site
  • Wielen, Poland, 64-730
    • Novartis Investigative Site
  • Wroclaw, Poland, 54-703
    • Novartis Investigative Site
  • Zgierz, Poland, 95-100
    • Novartis Investigative Site
  • POL
    • Chelm, POL, Poland, 22-100
      • Novartis Investigative Site
    • Kartuzy, POL, Poland, 83-300
      • Novartis Investigative Site
    • Warszawa, POL, Poland, 00-874
      • Novartis Investigative Site
• Portugal
  • Cantanhede, Portugal, 3060 123
    • Novartis Investigative Site
  • Leca da Palmeira, Portugal, 4450 586
    • Novartis Investigative Site
  • Lisboa, Portugal, 1200 375
    • Novartis Investigative Site
  • Lisboa, Portugal, 1250 210
    • Novartis Investigative Site
  • Lisboa, Portugal, 1800 192
    • Novartis Investigative Site
  • Oeiras, Portugal, 2780 163
    • Novartis Investigative Site
  • Bairro Novo
    • Seixal, Bairro Novo, Portugal, 2840 481
      • Novartis Investigative Site
• Russian Federation
  • Kazan, Russian Federation, 420012
    • Novartis Investigative Site
  • Moscow, Russian Federation, 127015
    • Novartis Investigative Site
  • Moscow, Russian Federation, 121552
    • Novartis Investigative Site
  • Moscow, Russian Federation, 121374
    • Novartis Investigative Site
  • Moscow, Russian Federation, 127206
    • Novartis Investigative Site
  • Petrozavodsk, Russian Federation, 185019
    • Novartis Investigative Site
  • Saint Petersburg, Russian Federation, 199106
    • Novartis Investigative Site
  • St.- Petersburg, Russian Federation, 197110
    • Novartis Investigative Site
  • Ufa, Russian Federation, 450000
    • Novartis Investigative Site
  • Vladivostok, Russian Federation, 690002
    • Novartis Investigative Site
  • Yaroslavl, Russian Federation, 150047
    • Novartis Investigative Site
• Slovenia
  • Ivancna Gorica, Slovenia, 1295
    • Novartis Investigative Site
  • Kranj, Slovenia, 4000
    • Novartis Investigative Site
  • Ljubljana, Slovenia, 1000
    • Novartis Investigative Site
  • Maribor, Slovenia, 2000
    • Novartis Investigative Site
  • Pesnica pri Mariboru, Slovenia, 2211
    • Novartis Investigative Site
  • Slovenske Konjice, Slovenia, 3210
    • Novartis Investigative Site
  • Spodnji Duplek, Slovenia, 2241
    • Novartis Investigative Site
  • Vrhnika, Slovenia, 1360
    • Novartis Investigative Site
  • Zalec, Slovenia, 3310
    • Novartis Investigative Site
• Spain
  • Alicante, Spain, 03540
    • Novartis Investigative Site
  • Coruna, Spain, 15007
    • Novartis Investigative Site
  • Madrid, Spain, 28033
    • Novartis Investigative Site
  • Madrid, Spain, 28030
    • Novartis Investigative Site
  • Madrid, Spain, 28032
    • Novartis Investigative Site
  • Panxon, Spain, 36340
    • Novartis Investigative Site
  • A Coruna
    • Cambre, A Coruna, Spain, 15660
      • Novartis Investigative Site
  • A Coruña
    • Porto do Son, A Coruña, Spain, 15970
      • Novartis Investigative Site
  • Alicante
    • Petrer, Alicante, Spain, 03610
      • Novartis Investigative Site
  • Almeria
    • El Parador De Las Hortichiuela, Almeria, Spain, 04720
      • Novartis Investigative Site
  • Asturias
    • Oviedo, Asturias, Spain, 33009
      • Novartis Investigative Site
    • Oviedo, Asturias, Spain, 33013
      • Novartis Investigative Site
  • Caceres
    • El canaveral, Caceres, Spain, 10820
      • Novartis Investigative Site
  • Cadiz
    • Puerto Real, Cadiz, Spain, 11510
      • Novartis Investigative Site
  • Castellon
    • Burriana, Castellon, Spain, 12530
      • Novartis Investigative Site
  • Islas Baleares
    • Alcudia, Islas Baleares, Spain, 07400
      • Novartis Investigative Site
  • Las Palmas De Gran Canaria
    • Telde, Las Palmas De Gran Canaria, Spain, 35215
      • Novartis Investigative Site
  • Madrid
    • Parla, Madrid, Spain, 28982
      • Novartis Investigative Site
  • Pontevedra
    • A Estrada, Pontevedra, Spain, 36681
      • Novartis Investigative Site
    • Monteporeiro, Pontevedra, Spain, 36162
      • Novartis Investigative Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Willing and able to provide written informed consent and accept study procedures and time schedule.
• Age ≥ 18 years.
• Patients suffering from chronic heart failure (the heart failure diagnosis must have been made or confirmed by a cardiologist and/or hospital physician at any time in the patient's medical history).
• Patients with reduced ejection fraction (≤ 40%) as confirmed at any time point in the patient's medical history.

Exclusion Criteria:

• Use of investigational drugs either within 5 half-lives of enrollment, or within 30 days, or until the expected pharmacodynamic effect has returned to baseline, whichever is longer.
• Major surgery in the last 3 months prior to baseline or planned major surgery or cardiac intervention during the study.
• Cancer or other significant co-morbidities implying that the patient's condition is unstable.
• Comorbidities that can be associated with elevated natriuretic peptide (NP) levels: renal insufficiency, (eGFR < 25 ml/min/1.73 m² calculated according to MDRD formula), recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months.
• Patients who are primarily managed and regularly followed-up by a cardiologist for their HF
• Highly frail patients whose estimated lifespan due to comorbidities by the judgement of the investigator is less than 6 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Patients' heart failure and non-heart failure; No treatments are stipulated by this protocol - patients' HF and non-HF treatments will be observed throughout the study. The patients' treatment is entirely in the discretion of the primary care physicians	Procedure: Standard care; Patients will receive the treatment that their primary care physician has decided to prescribe for their disease

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Clinically Stable Patients Whose Therapy Regimen Adheres to ESC Guideline Recommendations for Drug Types (Level 1) and Drug Type and Dose (Level 2) at Visit 1 (Before Referral to a Cardiologist)	Assessment of treatment regimen with respect to ESC guideline adherence at Visit 1 before referral to cardiologist. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF > 35% at visit 1. Drug type & dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.	Baseline (Visit 1)
Adherence to ESC Guideline at Visit 2 (After Referral to a Cardiologist, Month 6), for Follow-up Set: Drug Type and Drug Type and Dose	Assessment of patients' adherence at Visit 2, for patients who were already adherent at Visit 1, and those who were not adherent at Visit 1, for both drug type and drug type and dose. ESC Criteria for adherence: Drug Types: Treatment with (1) ACEi or (1) ARB in combination with (1) beta-blocker and (1) MRA for patients w/an LVEF ≤ 35% at V1. Treatment w/(1) ACEi or (1) ARB, in combination with (1) beta-blocker+ without treatment with an MRA for patients with an LVEF > 35% at visit 1. Drug type & dose: Guideline adherent with respect to drug types and dosage of all respective guideline drugs ≥ 50% of the recommended target dose.	Month 6

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Duration of Heart Failure	The duration of Heart Failure was collected at Baseline (Visit 1).	Baseline (Visit 1)
Number of Patients With Current Use of Concomitant Compound	Use of concomitant compounds were collected at baseline (Visit 1)	Baseline (Visit 1)
Number of Follow-Up Patients With Current Use of Concomitant Compound at Visit 2	Use of concomitant compounds were collected at 6 months (Visit 2)	6 months (Visit 2)
Percentages of Clinically Stable Patients for Whom the Cardiologist and/or Primary Care Physician Optimizes Treatment Post Referral, Stratified According to Key Baseline Characteristics	For patients who enter the prospective period of the study the post-referral treatment choice of cardiologists and/or primary care physicians was documented; for patients, for whom the cardiologist and/or primary care physician chose to prescribe a novel Heart Failure treatment, the treatment was assessed, if it fulfills the definition of adherence to European Society of Cardiology (ESC) guideline recommendation. The proportion of patients for whom an ESC guideline adherent treatment was de novo prescribed was assessed stratified according to different parameters.	6 months
Number of Patients With Different NT-proBNP Level Categories	NT-proBNP levels (pg/ml) was measured at baseline in all consecutive patients who satisfy the inclusion and exclusion criteria. Measurements were performed on-site by means of a handheld device provided for the purposes of the study. NT-proBNP level categories could be 600 -799 pg/ml, 800 - 999 pg/ml, 1000 - 1200 pg/ml, > 1200 pg/ml).	One measurement in all consecutive patients at baseline (Visit 1)
Percentages of Clinically Stable Patients	Clinically stable patients in this study were defined as those patients for whom the primary care physician did not see a necessity (based on signs and symptoms of HF) to change the current pharmacological and/or device treatment of HF and who were on stable pharmacological and/or device treatment for HF for at least 3 months prior to inclusion.	Baseline (Visit 1)
Number of Patients by Cardiologist Prescription Practice Per Country/Region	The cardiologists' suggestions for pharmacological and/or device therapy for the treatment of clinically stable CHF patients was documented and assessed by means of descriptive statistical measures stratified by country/region 6 months after baseline.	6 months
Change of NT-proBNP Levels in Clinically Stable Chronic Heart Failure Patients With and Without Treatment Optimization 10 Months After Baseline	At 10 months after baseline (end of study) NT-proBNP was assessed in clinically stable CHF patients with baseline NT-proBNP levels ≥ 600 pg/ml. Thus, for those patients two NT-proBNP measurements were available: at baseline and 10 months later. The individual change of NT-proBNP between both time points were assessed in accordance to the patients' treatment history during the study, i.e. baseline Heart Failure treatment and therapeutic decision taken 6 months after baseline.	10 months
Change in EuroQol Five Dimensions Questionnaire (EQ-5D) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)	Quality of life (QoL) was assessed by EQ-5D including the dimensions mobility, self-care, usual activity, pain/discomfort, anxiety/depression. A utility index based on UK value sets was built to summarize the information of these five dimensions into a single scale. The utility index can range between -0.281 and 1.0 where a higher number indicates a better health status. In addition, a visual analog scale (VAS) was applied with a possible range between 0 (=worst imaginable health state) and 100 (=best imaginable health state). Scores collected for all patients at baseline (Visit 1) and at Visit 2 and Visit 3 (only patients who entered the prospective period of the study, i.e. clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to fill out the EuroQol 5D (EQ-5D) quality of life (QoL) questionnaire validated for heart failure (HF).	Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3)
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Total and Individual Sub-scores at Visit 1 (Baseline), Visit 2 (6 Months) and Visit 3 (10 Months)	The KCCQ is a self-administered questionnaire. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and quality of life, each with different Likert scale wording, including limitations, frequency, bother, change in condition, understanding, levels of enjoyment and satisfaction. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. A positive change from baseline indicates improvement. Scores were collected for all patients at baseline and Visit 2 and Visit 3 (only patients who had entered the prospective period of the study (clinically stable patients with a NT-proBNP level ≥ 600 pg/ml) were asked to complete Kansas City Cardiomyopathy Questionnaire (KCCQ) validated for Heart Failure.	Baseline (Visit 1), 6 months (Visit 2), 10 months (Visit 3)
Number of Patients in Different Living Conditions	Living conditions were collected at Baseline (Visit 1).	Baseline (Visit 1)
Number of Patients in Different Employment Status	Employment status was collected at Baseline (Visit 1).	Baseline (Visit 1)
Number of Patients With Smoking Status	Smoking status was collected at baseline (visit 1).	Baseline (Visit 1)
Number of Patients From Different Geographical Regions	Geographic regions were collected at Baseline (Visit 1).	Baseline (visit 1)
Number of Patients With Health Insurance Status	Health insurance status was collected at Baseline (Visit 1).	Baseline (Visit 1)
Number of Patients at Different Educational Level	Educational level was collected at Baseline (Visit 1).	Baseline (Visit 1)
Number of Patients Per Primary Etiology of Heart Failure	The primary etiology of Heart Failure was collected at Baseline (Visit 1).	Baseline (Visit 1)
Number of Patients With Heart Failure (HF)-Related Hospitalizations in the Previous 12 Months Prior to Baseline, and During the Study	HF-related hospitalizations was collected in the previous 12 months prior to baseline at baseline visit, at 6 and 10 months post-baseline.	Baseline (Visit 1), 6 months, 10 months
Percentage of Patients With Cardiovascular and Non-cardiovascular Co-morbidities	Cardiovascular and non-cardiovascular co-morbidities were collected at baseline (Visit 1)	Baseline (Visit 1)
Mean Dose of Previously Taken and Current Use of Concomitant Medications	Mean Dose of previously taken and current use of concomitant medications was to be collected at Visit 1, 6 months, 10 months post-baseline	Baseline (Visit 1), 6 months, 10 months
Number of Heart Failure (HF) Treatment Combinations	The types and number of participants with HF treatment combinations were collected at Baseline (Visit 1).	Baseline (Visit 1)
Duration of Treatment With Device Type	The duration of treatment with device type was collected at baseline (Visit 1)	Baseline (Visit 1)
Duration of Previously Taken and Currently Use of Most Common Non-Heart Failure Concomitant Compounds	Duration of most common previously taken and current use of most common Non-HF concomitant compounds were collected	Baseline (Visit 1)
Number of Patients by Primary Care Physicians' Prescription Practice Per Country/Region	For clinically stable CHF patients, the primary care physicians' prescription of pharmacological and device treatment for HF was to be documented prior to baseline and post cardiologist-referral. At the post-referral visit the degree of implementation of cardiologist-recommendations and the medical decision making (e.g. reasons for non-implementation) were to be documented.	Baseline (Visit 1)

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start (Actual): July 7, 2016
• Primary Completion (Actual): March 23, 2018
• Study Completion (Actual): March 23, 2018

Study Registration Dates

• First Submitted: June 17, 2016
• First Submitted That Met QC Criteria: June 17, 2016
• First Posted (Estimate): June 21, 2016

Study Record Updates

• Last Update Posted (Actual): February 24, 2021
• Last Update Submitted That Met QC Criteria: February 2, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: heart failure,; low-interventional observational study,; CHF,; primary care,; ESC guidelines,; Europe,; NT-proBNP,; reduced ventricular ejection fraction (EF),
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure
• Other Study ID Numbers: CLCZ696B3402; 2016-000473-20 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Yes
• IPD Plan Description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No